Disclosure of large-scale exercise of the 16th stock acquisition rights. From August 1, 2026 onward, 210,000 shares issued, total 416 rights exercised out of 17,000 issued, exercise ratio 12.4%, unexercised rights currently 0. Unknown points are unknown.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Crinkles Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4884-20260827-02.pdf","jir_short_summary":"Disclosure of large-scale exercise of the 16th stock acquisition rights. From August 1, 2026 onward, 210,000 shares issued, total 416 rights exercised out of 17,000 issued, exercise ratio 12.4%, unexercised rights currently 0. Unknown points are unknown.","jir_summary":"### Background and issuance status\nThis stock acquisition right relates to the 16th stock acquisition right (with exercise price adjustment clause) issued through a third-party allotment announced on July 16, 2025, and clarifies the large-scale exercise status from August 1, 2026. As of July 30, 2026, the number of issued shares was 8,383,200, of which 183 were treasury shares. Disbursed shares are 210,000, and total rights issued are 17,000.\n\n### Exercise status and unexercised rights\nFrom August 1, 2026 onward, exercise status is disclosed by date, and on August 12, 2026, 17,000 stock acquisition rights were exercised for 416 shares, with 170 shares recorded as transferred treasury shares. Further exercises occurred from August 13 to 27, bringing total exercised to 416 shares. Unexercised stock acquisition rights were 0 as of July 31, and remain 0 currently.","jir_financial_highlights":"Disbursed shares: 210,000 \u682a (Period start)\nNumber of stock acquisition rights exercised: 416 \u500b (Cumulative within period)\nTotal stock acquisition rights issued: 17,000 \u500b (Current cumulative)","jir_category":"","jir_hashtags":"#CrinklesPharmaceuticalCo.,Ltd., #StockAcquisitionRight, #StockOption","jir_key_figures":"Disbursed shares: 210,000 \u682a\nNumber of stock acquisition rights exercised: 416 \u500b\nTotal stock acquisition rights issued: 17,000 \u500b","jir_meta_title":"\u3010CrinklesPharmaceuticalCo.,Ltd.\u3011Notice of Large-Scale Exercise of the 16th Stock Acquisition Rights Issued via Third-Party Allotment | August 2026","jir_meta_description":"CrinklesPharmaceutical reports large-scale exercise of the 16th stock acquisition rights issued. Disbursed shares: 210,000; exercised: 416; unexercised rights: 0. Total issued rights: 17,000. Impact going forward is unknown.","jir_og_title":"\u3010CrinklesPharmaceuticalCo.,Ltd.\u3011Notice of Large-Scale Exercise of the 16th Stock Acquisition Rights","jir_og_description":"Disclosure of large-scale exercise of stock acquisition rights. Disbursed shares: 210,000; exercised: 416; total issued rights: 17,000. Unexercised rights: 0.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-107738","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n